secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001564590-22-037625
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences Q3 net loss $13.1M; Phase 3 ORCA-3 and Phase 2 ORCA-V1 enrollment completed
--------------------------------------------------------------------------------

- Net loss of $13.1M for Q3 2022; operating expenses $12.6M; cash and restricted cash $18.2M as of Sept 30, 2022.
- Phase 3 ORCA-3 trial of cytisinicline enrolled 750 adult smokers; topline data expected Q2 2023.
- Phase 2 ORCA-V1 trial of cytisinicline in 150 e-cigarette users completed enrollment early; topline data expected Q2 2023.
- Sopharma completed new API purification suite for cytisinicline with >€3M cost, expanding global production capacity.
- 9,710,747 shares outstanding as of Nov 10, 2022; no revenue (pre-commercial stage).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/0001564590-22-037625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/achv-8k_20221114.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-037625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer